Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DVAXNASDAQ:GTHXNASDAQ:HGENNASDAQ:SNDXOTCMKTS:VEGPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDVAXDynavax Technologies$10.28+1.2%$10.14$9.22▼$14.63$1.23B1.032.16 million shs511,141 shsGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/AHGENHumanigen$0.00$0.00▼$0.24$24K-1.043.26 million shs2.06 million shsSNDXSyndax Pharmaceuticals$9.28+3.1%$10.50$8.58▼$25.07$774.42M0.71.84 million shs817,852 shsVEGPFVectura Group$1.77$1.77$1.64▼$2.74$1.07B0.372,185 shsN/A12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDVAXDynavax Technologies0.00%+3.73%+3.94%-18.74%-6.72%GTHXG1 Therapeutics0.00%0.00%0.00%0.00%+178.21%HGENHumanigen0.00%0.00%0.00%0.00%0.00%SNDXSyndax Pharmaceuticals0.00%+2.61%-15.36%-17.55%-53.80%VEGPFVectura Group0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDVAXDynavax Technologies4.1976 of 5 stars3.32.00.04.70.61.71.9GTHXG1 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHGENHumanigenN/AN/AN/AN/AN/AN/AN/AN/ASNDXSyndax Pharmaceuticals3.1516 of 5 stars3.51.00.04.41.20.00.0VEGPFVectura GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDVAXDynavax Technologies 2.50Moderate Buy$24.00133.46% UpsideGTHXG1 Therapeutics 2.00HoldN/AN/AHGENHumanigen 0.00N/AN/AN/ASNDXSyndax Pharmaceuticals 2.90Moderate Buy$35.80285.94% UpsideVEGPFVectura Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GTHX, DVAX, HGEN, VEGPF, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025DVAXDynavax TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.005/6/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.005/6/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/17/2025DVAXDynavax TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$12.00 ➝ $10.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDVAXDynavax Technologies$277.25M4.45$0.16 per share64.86$4.54 per share2.26GTHXG1 Therapeutics$58.20M6.42N/AN/A$0.68 per share10.51HGENHumanigen$1.70M0.00N/AN/A($0.45) per share0.00SNDXSyndax Pharmaceuticals$43.72M18.26N/AN/A$3.38 per share2.74VEGPFVectura Group$244.76M4.37$0.28 per share6.33$1.16 per share1.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDVAXDynavax Technologies$27.31M-$0.52N/A20.98N/A-20.39%3.59%2.20%8/5/2025 (Estimated)GTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/AHGENHumanigen-$70.73MN/A0.00N/AN/AN/AN/AN/AN/ASNDXSyndax Pharmaceuticals-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)VEGPFVectura Group$157.16M$0.266.8117.70N/AN/AN/AN/AN/ALatest GTHX, DVAX, HGEN, VEGPF, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025DVAXDynavax Technologies$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 million5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDVAXDynavax TechnologiesN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/AHGENHumanigenN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDVAXDynavax Technologies0.4911.9310.84GTHXG1 Therapeutics1.342.482.12HGENHumanigenN/AN/AN/ASNDXSyndax Pharmaceuticals1.535.805.75VEGPFVectura GroupN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDVAXDynavax Technologies96.96%GTHXG1 Therapeutics24.21%HGENHumanigen4.55%SNDXSyndax PharmaceuticalsN/AVEGPFVectura GroupN/AInsider OwnershipCompanyInsider OwnershipDVAXDynavax Technologies2.98%GTHXG1 Therapeutics6.11%HGENHumanigen21.70%SNDXSyndax Pharmaceuticals4.10%VEGPFVectura GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDVAXDynavax Technologies350120.08 million116.50 millionOptionableGTHXG1 Therapeutics17052.28 million49.09 millionOptionableHGENHumanigen6119.08 million93.24 millionNo DataSNDXSyndax Pharmaceuticals11086.05 million82.52 millionOptionableVEGPFVectura Group502604.26 millionN/ANot OptionableGTHX, DVAX, HGEN, VEGPF, and SNDX HeadlinesRecent News About These CompaniesPhilip Morris closes on the sale of Vectura GroupJanuary 2, 2025 | msn.comM&A News: Philip Morris (NYSE:PM) Will Sell Vectura for $198MSeptember 17, 2024 | msn.comVectura and Hikma to develop US asthma genericAugust 20, 2024 | pharmaphorum.comPEuropean Stocks See Mixed Session as U.K.'s FTSE LeadsJanuary 16, 2023 | thestreet.comVECTURA GROUP LS -,000271 (V4TA.BE)January 15, 2023 | finance.yahoo.comVectura Group PLC (V4TA.BE)January 9, 2023 | finance.yahoo.comResults for 'Vectura-Fertin Pharma'October 11, 2022 | afaqs.comAVectura Group (OTC:VEGPF), Short Interest ReportJuly 18, 2022 | benzinga.comCarlyle stays in race for VecturaAugust 27, 2021 | uk.finance.yahoo.comForm 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826August 27, 2021 | finance.yahoo.comPhilip Morris chief attacks critics as Vectura bid tests investorsAugust 20, 2021 | uk.finance.yahoo.comMarkets: FTSE inches to new post-pandemic high as Vectura takeover draws closerAugust 13, 2021 | uk.finance.yahoo.comVectura auction called off after Carlyle declines to beat Philip Morris bidAugust 10, 2021 | uk.finance.yahoo.comUPDATE 1-Vectura takeover battle could slip into auction - UK regulatorAugust 9, 2021 | finance.yahoo.comPhilip Morris, Carlyle could fight it out for UK's Vectura in auction ringAugust 9, 2021 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTHX, DVAX, HGEN, VEGPF, and SNDX Company DescriptionsDynavax Technologies NASDAQ:DVAX$10.28 +0.12 (+1.18%) Closing price 07/3/2025 03:20 PM EasternExtended Trading$10.28 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.G1 Therapeutics NASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Humanigen NASDAQ:HGENHumanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Syndax Pharmaceuticals NASDAQ:SNDX$9.28 +0.28 (+3.07%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$9.15 -0.13 (-1.36%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Vectura Group OTCMKTS:VEGPF$1.77 0.00 (0.00%) As of 11/1/2021Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
